http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pregnancy Rates and Outcomes of HIV-Infected Women in Korea
최흔,김무현,이세주,김은진,이운지,정우용,정인영,안진영,정수진,구남수,백지현,최영화,김효열,김준명,최준용 대한의학회 2018 Journal of Korean medical science Vol.33 No.47
Background: Antepartum, intrapartum, and postpartum preventive measures with antiretroviral drugs, appropriate delivery methods, and discouraging breastfeeding significantly decrease the risk of mother-to-child transmission of human immunodeficiency virus (HIV) infection. Herein, we investigated the pregnancy outcomes in HIV-infected Korean women. Methods: We retrospectively reviewed medical records of childbearing-age HIV-infected women between January 2005 and June 2017 at four tertiary care hospitals in Korea. Results: Among a total of 95 HIV infected women of child-bearing age with 587.61 years of follow-up duration, 15 HIV-infected women experienced 21 pregnancies and delivered 16 infants. The pregnancy rate was 3.57 per 100 patient-years. Among the 21 pregnancies, five ended with an induced abortion, and 16 with childbirth including two preterm deliveries at 24 and 35 weeks of gestation, respectively. The two preterm infants had low birth weight and one of them died 10 days after delivery due to respiratory failure. Among the 14 full-term infants, one infant was small for gestational age. There were no HIV-infected infants. Conclusion: The pregnancy rate of HIV-infected women in Korea is lower than that of the general population. Although several adverse pregnancy outcomes were observed, mother- to-child transmission of HIV infection was successfully prevented with effective preventive measures.
최흔,최준용,이혜원,김재경,강화평,김선욱,구남수,한상훈,김준명 대한감염학회 2014 Infection and Chemotherapy Vol.46 No.4
Diffuse large B cell lymphoma (DLBCL) is one of the most common acquired immune deficiency syndrome (AIDS)-definingmalignancies among human immunodeficiency virus -infected patients, and rectal cancer has recently emerged as a prevalentnon-AIDS-defining malignancy. We report a case of rectal squamous cell carcinoma that was metachronous with DLBCL in anHIV-infected patient who was receiving highly active antiretroviral therapy. The patient was diagnosed with DLBCL and showedcomplete remission after chemotherapy. Follow-up imaging showed increased uptake at the rectum, previously treated as lymphoma. Repeated biopsy was performed and squamous cell carcinoma of the rectum was reported. After concurrent chemoradiationtherapy, curative resection was performed.
최승임,최흔,박성연,곽이경,송제은,신소연,백지현,신현일,오홍상,김용찬,염준섭,한진희,김민재 대한기생충학ㆍ열대의학회 2022 The Korean Journal of Parasitology Vol.60 No.1
Plasmodium vivax exhibits dormant liver-stage parasites, called hypnozoites, which can cause relapse of malaria. The only drug currently used for eliminating hypnozoites is primaquine. The antimalarial properties of primaquine are dependent on the production of oxidized metabolites by the cytochrome P450 isoenzyme 2D6 (CYP2D6). Reduced primaquine metabolism may be related to P. vivax relapses. We describe a case of 4 episodes of recurrence of vivax malaria in a patient with decreased CYP2D6 function. The patient was 52-year-old male with body weight of 52 kg. He received total gastrectomy and splenectomy 7 months before the first episode and was under chemotherapy for the gastric cancer. The first episode occurred in March 2019 and each episode had intervals of 34, 41, and 97 days, respectively. At the first and second episodes, primaquine was administered as 15 mg for 14 days. The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes. Seven gene sequences of P. vivax were analyzed and revealed totally identical for all the 4 samples. The CYP2D6 genotype was analyzed and intermediate metabolizer phenotype with decreased function was identified.
의료기관 종사자 대상 Pfizer와 AstraZeneca COVID-19 백신 2회 접종 후 항체검사 검출률
노경호,최흔,최희경,윤미선,유종하,박윤선 대한임상미생물학회 2022 Annals of clinical microbiology Vol.25 No.3
Background: Due to the COVID-19 pandemic, from 2020, many pharmaceutical companieshave developed vaccines. To determine the efficacy of AstraZeneca's and Pfizer's vaccines,which were the first and second vaccines to be approved in Korea, respectively, we developeda method to measure their antibody-generating efficacies using immunology analyzers and arapid antibody test available in Korea. Methods: The antibody-stimulating efficacies of the Pfizer and AstraZeneca vaccines wereevaluated using Centaur® XPT SARS-CoV-2 (Siemens Healthineers, Germany), Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Germany), and STANDARD F SARS-CoV-2 nAb FIA (SDBiosensor, Korea). Healthcare workers were enrolled in two groups: the Pfizer (121) andAstraZeneca (117) groups. Antibody levels were measured pre-vaccination, three weeks aftervaccination, and 16 weeks after vaccination. Results: The Pfizer group comprised 41 males and 80 females, while the AstraZenecagroup comprised 38 males and 79 females. Antibody results were analyzed after excludingfour individuals who had recovered from COVID-19. Between weeks 3 and 16, there was nosignificant difference (P= 0.5, 1.0) between the results of the Roche and Siemens antibodytests in the Pfizer vaccine group. However, the SD biosensor results comparing with the Rocheand Siemens antibody tests at three weeks after the initial vaccination showed a significantdifference (P < 0.0001). Analysis of the Roche antibody test results before, at three weeks, and at16 weeks after the administration of the Pfizer and AstraZeneca vaccines revealed a statisticallysignificant difference between before and at three weeks after the first injection (P < 0.0001). Conclusion: After two doses of the Pfizer and AstraZeneca vaccines, antibody formation wasabove the 90th percentile of the measurement range in all subjects.
최준용,오진옥,안진영,최흔,김정호,성혜,정수진,구남수,염준섭,최재필 대한백신학회 2019 Clinical and Experimental Vaccine Research Vol.8 No.1
We evaluated the neutralizing activity in serum from three patients >1 year after recovery from Middle East respiratory syndrome (MERS) associated with mild pneumonia treated with antivirals during the MERS outbreak in South Korea at 2015. The neutralizing activity in serum was measured by pseudovirus inhibition assays. Three-fold diluted serum of subjects showed only 9.7%, 10.3%, and 2.2% reductions in relative light units. So, significant neutralizing activity was not demonstrated in any sera of three patients with mild pneumonia >1 year after being successfully treated with antiviral agents and recovering from MERS coronavirus infection.